EEA (European Economic Area) vigilance reports continue out of kilter
This article was originally published in Clinica
Executive Summary
The number of vigilance reports being issued by Germany continues to be far out of line with the number being issued by other countries in the European Economic Area. In the 10 weeks since July 31, Germany has issued 20 reports concerning products covered by the Medical Devices Directive and the Active Implantable Medical Devices Directive, compared with 14 in total issued by all other EEA countries.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.